Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Dexmedetomidine as an Adjuvant to Bupivacaine in Fascia Iliaca Block for Femoral Fracture Surgery Under General Anesthesia: A Dose-Finding Study (FIB-DEX)

17. november 2026 opdateret af: Alaa mahmoud bahaa eldin mohamed taha, Cairo University

Dexmedetomidine Added to Bupivacaine in Fascia Iliaca Block Combined With General Anesthesia for Femoral Fracture Surgery: A Dose-Finding Randomized Double-Blind Study

### Brief Summary

Femoral fractures can cause severe pain during and after surgery. Although fascia iliaca block is commonly used to relieve pain in patients undergoing femoral fracture surgery, the duration of pain relief may be limited.

Dexmedetomidine is a medication that may prolong the pain-relieving effect of local anesthetics such as bupivacaine. However, the most appropriate dose of dexmedetomidine for this type of nerve block is not yet clearly established.

This study aims to determine the lowest effective dose of dexmedetomidine when added to bupivacaine for ultrasound-guided fascia iliaca block in patients undergoing femoral fracture surgery under general anesthesia.

The study includes 90 adult patients, aged 18-75 years, who are scheduled for femoral fracture surgery. Participants will be randomly assigned to one of three groups, with 30 patients in each group. All patients will receive general anesthesia and an ultrasound-guided fascia iliaca block containing 30 mL of 0.25% bupivacaine, combined with one of the following doses of dexmedetomidine:

  • Group A: 0.5 micrograms/kg.
  • Group B: 0.75 micrograms/kg.
  • Group C: 1 microgram/kg.

Neither the patients nor the doctors assessing the study outcomes will know which dose has been administered.

Pain levels will be assessed during the first 24 hours after surgery using a numerical pain scale. The study will also measure the time until patients first require additional pain medication and the total amount of pain medication used.

Other assessments will include leg muscle strength, level of sedation, heart rate, blood pressure, and any possible side effects or complications.

The main purpose of this study is to identify the lowest dose of dexmedetomidine that provides effective postoperative pain relief while minimizing unwanted effects, helping improve pain management and recovery after femoral fracture surgery.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

90

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

Age between 18-75 years. both sexes. American Society of Anesthesiologists (ASA) physical status I-III Scheduled for femoral fracture surgery

Exclusion Criteria:

Allergy to study drugs. Heart block type II. Pre-existing neurologic or psychiatric disease. Severe hepatic or renal impairment. Infection at injection site.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: dexmedetomidine 0.5

Name: Dexmedetomidine 0.5 µg/kg with bupivacaine for supra-inguinal fascia iliaca block

Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 0.5 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesia

Intervention 1 - Group dexmeditomidine 0.5

Dexmedetomidine 0.5 µg/kg with bupivacaine for supra-inguinal fascia iliaca block

Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 0.5 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesia.

---

Andre navne:
  • bupivacain
Aktiv komparator: dexmedetomidine 0.75

Name: Dexmedetomidine 0.75 µg/kg with bupivacaine for supra-inguinal fascia iliaca block

Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 0.75 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesia.

Name: Dexmedetomidine 0.75 µg/kg with bupivacaine for supra-inguinal fascia iliaca block

Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 0.75 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesia.

Aktiv komparator: dexmedetomidine 1

Name: Dexmedetomidine 1 µg/kg with bupivacaine for supra-inguinal fascia iliaca block

Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 1 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesi

Name: Dexmedetomidine 1 µg/kg with bupivacaine for supra-inguinal fascia iliaca block

Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 1 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesia.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Time to the first request for rescue analgesia in minutes
Tidsramme: from end of surgery to the first request for nalbuphine

time in minutes to first rescue analgesia will be measured.

from end of surgery to the first request for nalbuphine

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
postoperative pain assessed as Numerical rating score (NRS)
Tidsramme: from 30 minutes after surgery to 24 hours after surgery
from 30 minutes after surgery to 24 hours after surgery
motor block using modified bromage scale
Tidsramme: from 30 minutes to 24 hours after surgery
from 30 minutes to 24 hours after surgery
total nalbuphine consumption in milligram (mg)
Tidsramme: from end of surgery to 24 hours after surgery
from end of surgery to 24 hours after surgery
heart rate
Tidsramme: starting before general anesthesia till 60 minutes after surgery
starting before general anesthesia till 60 minutes after surgery
sedation score
Tidsramme: from 30 minutes after the end of operations to 24 hours postoperative .

using ramsay sedation scale

from 30 minutes after the end of operations to 24 hours postoperative .
mean arterial pressure
Tidsramme: starting before general anesthesia till 60 minutes after surgery
starting before general anesthesia till 60 minutes after surgery
systolic blood pressure
Tidsramme: starting before general anesthesia till 60 minutes after surgery
starting before general anesthesia till 60 minutes after surgery
diastolic blood pressure
Tidsramme: starting before general anesthesia till 60 minutes after surgery
starting before general anesthesia till 60 minutes after surgery

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

15. december 2026

Primær færdiggørelse (Anslået)

1. marts 2027

Studieafslutning (Anslået)

1. april 2027

Datoer for studieregistrering

Først indsendt

11. november 2026

Først indsendt, der opfyldte QC-kriterier

17. november 2026

Først opslået (Faktiske)

19. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

19. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

17. november 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner